TattersallR. Diabetes: the biography. Oxford: Oxford University Press; 2009.
2.
American Diabetes Association. Standards of medical care in diabetes–2011. Diabetes Care. 2011; 34Suppl 1: S11–61.
3.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329 (14): 977–86.
4.
NathanDMBuseJBDavidsonMBFerranniniEHolmanRRSherwinRZinmanB; American Diabetes Association; European Association for the Study of Diabetes, Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009; 52 (1): 17–30.
5.
NolanJJ. Consensus guidelines, algorithms and care of the individual patient with type 2 diabetes. Diabetologia. 2010; 53 (7): 1247–9.
6.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352 (9131): 837–53.
7.
YudkinJSRichterBGaleEA. Intensified glucose lowering in type 2 diabetes: time for a reappraisal. Diabetologia. 2010; 53 (10): 2079–85.
8.
HollemanFGaleEA. Nice insulins, pity about the evidence. Diabetologia. 2007; 50 (9): 1783–90.
9.
WaughNCumminsERoylePClarCMarienMRichterBPhilipS. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health Technol Assess. 2010; 14 (36): 1–248.
10.
NathanDMBuseJBDavidsonMBFerranniniEHolmanRRSherwinRZinmanB; American Diabetes Association; European Association for Study of Diabetes, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32 (1): 193–203.
11.
HolmanRRFarmerAJDaviesMJLevyJCDarbyshireJLKeenanJFPaulSK; 4-T Study Group, Three-year efficacy of complex insulin regimens in type 2 diabetes. N Eng J Med. 2009; 361 (18): 1736–47.
12.
KannPHWascherTZackovaVMoellerJMeddingJSzocsAMokanMMrevljeFRegulskiM. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006; 114 (9): 527–32.
13.
LieblAPragerRBinzKKaiserMBergenstalRGallwitzB; PREFER Study Group, Comparison of Insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diab Obesity Metab. 2009; 11 (1): 45–52.
14.
RaskinPAllenEHollanderPLewinAGabbayRAHuPBodeBGarberA; INITIATE Study Group, Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005; 28 (2): 260–5.
15.
BuseJBWolffenbuttelBHHermanWHShemonskyNKJiangHHFahrbachJLScism-BaconJLMartinSA. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009; 32 (6): 1007–13.
16.
BretzelRGNuberULandgrafWOwensDRBradleyCLinnT. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet. 2008; 371 (9618): 1073–84.
17.
MaloneJKKerrLFCampaigneBNSachsonRAHolcombeJH; Lispro Mixture-Glargine Study Group, Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004; 26 (12): 2034–44.
18.
MaloneJKBaiSCampaigneBNReviriegoJAugendre-FerranteB. Twice-daily pre-mixed Insulin rather than basal Insulin therapy alone results in better overall glycaemic control in patients with type 2 diabetes. Diabet Med. 2005; 22 (4): 374–81.
19.
KazdaCHülstrunkHHelsbergKLangerFForstTHanefeldM. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complications. 2006; 20 (3): 145–52.
20.
JacoberSJScism-BaconJLZagarAJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents. Diab Obesity Metab. 2006; 8 (4): 448–55.
21.
HiraoKAraiKYamauchiMTakagiHKobayashiM; Japan Diabetes Clinical Data Management Study Group, Six-month multi-centric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). Diabetes Res Clin Prac. 2008; 79 (1): 171–6.
22.
RobbinsDCBeisswengerPJCerielloAGoldbergRBMosesRGPagkalosEMMilicevicZJonesCASarwatSTanMH. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2007; 29 (11): 2349–64.
23.
RosenstockJAhmannAJColonGScism-BaconJJiangHMartinS. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care. 2008; 31 (1): 20–5.
